RNAZ — Transcode Therapeutics Balance Sheet
0.000.00%
- $5.49m
- $0.58m
- 10
- 28
- 23
- 10
Annual balance sheet for Transcode Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.204 | 0.828 | 20.8 | 4.98 | 2.77 |
Net Total Receivables | — | — | — | 0.36 | — |
Prepaid Expenses | |||||
Total Current Assets | 0.204 | 0.831 | 22.7 | 7.38 | 4.46 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | — | — | 0.206 | 0.209 | 0.602 |
Other Long Term Assets | |||||
Total Assets | 0.204 | 1.06 | 22.9 | 7.59 | 5.17 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.063 | 0.405 | 2.53 | 4.35 | 3.49 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.31 | 4.46 | 2.53 | 4.35 | 3.53 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -1.11 | -3.41 | 20.4 | 3.24 | 1.64 |
Total Liabilities & Shareholders' Equity | 0.204 | 1.06 | 22.9 | 7.59 | 5.17 |
Total Common Shares Outstanding |